Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 马碧如教授 (肿瘤学系) |
| 陈林教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) ○○@http://aims.cuhk.edu.hk/converis/portal/Publication/3$@○○ |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/3WOS source URL
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/3Scopus source URL
其它资讯
摘要Introduction: Regorafenib is a multi-targeted kinase inhibitor that has been approved recently for the treatment of certain gastrointestinal (GI) cancers. This review examines the scientific evidence on the efficacy and safety of this agent in Phase I to III studies. Areas covered: A literature review was performed based on published studies from PubMed and abstracts from international conferences. Expert opinion: Regorafenib has expanded the treatment options of patients with treatment-refractory gastrointestinal stromal tumor (GIST) and metastatic colorectal cancer (CRC). Ongoing studies are now investigating the activity of regorafenib as earlier line of therapy in CRC as monotherapy or in combination with chemotherapy. In the next 5 years, the activity of regorafenib will be further defined in other cancers such as renal cell cancer (RCC), hepato-biliary and upper GI cancers. In terms of safety, clinical trials suggest that the incidence and severity of toxicities may be higher in certain populations such as those with RCC or GIST. However, most of the common toxicities of regorafenib could be managed with dose modification without resorting to permanent drug discontinuation. Education of both patients and clinicians is thus important in minimizing treatment-related toxicities and improving drug compliance.
着者Chan S.L., Ma B.B.Y.
期刊名称Expert Opinion on Drug Metabolism and Toxicology
出版年份2014
月份1
日期1
卷号10
期次11
出版社Ashley Publications Ltd.
出版地United Kingdom
页次1607 - 1614
国际标準期刊号1742-5255
电子国际标準期刊号1744-7607
语言英式英语
关键词Colorectal cancer, GIST, Phase I studies, Regorafenib, Renal cell cancer, Toxicity
